O3‐05‐01: Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease-Reference-Cited by-同舟云学术

O3‐05‐01: Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease

Published:2010-07 Issue:4S_Part_4 Volume:6 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Blennow Kaj¹,Zetterberg Henrik¹,Wei Jenny²,Liu Enchi³,Black Ronald⁴,Grundman Michael²

Affiliation:

1. Sahlgrenska Academy at University of GothenburgGothenburg Sweden

2. JANSSEN Alzheimer Immunotherapy Research & DevelopmentSouth San Francisco CA USA

3. JANSSEN Alzheimer Immunotherapy Research & Development LLCSouth San Francisco CA USA

4. Pfizer, Inc.Collegeville PA USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2010.05.419

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease;Antibodies;2023-06-19

2. Curcumin Offers Potential Efficacy for Treating Alzheimer’s Disease;Curcumin for Neurological and Psychiatric Disorders;2019

3. Current status of vaccination therapies in Alzheimer's disease;Journal of Neurochemistry;2012-10-11

4. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies;Immunotherapy;2012-02

5. Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics;Development of Antibody-Based Therapeutics;2012